公开(公告)号：US10912824B2

公开(公告)日：2021-02-09

申请号：US15325124

申请日：2015-07-13

Applicant: Ospedale San Raffaele S.R.L. ,  Fondazione Telethon

Inventor： Alessio Cantore ,  Angelo Leone Lombardo ,  Luigi Naldini

IPC: A61K39/12 ,  C12N7/04 ,  C12N15/86

Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.

公开(公告)号：US20210015834A1

公开(公告)日：2021-01-21

申请号：US16968628

申请日：2019-02-26

Applicant: OSPEDALE SAN RAFFAELE S.R.L.

Inventor： Paolo RAMA ,  Giulio FERRARI

IPC: A61K31/675 ,  A61P27/02

Abstract: The invention relates to compounds, in particular NK-1 antagonists, for use in the treatment of ocular sensitivity and/or ocular pain.

公开(公告)号：US20200278356A1

公开(公告)日：2020-09-03

申请号：US16477812

申请日：2018-01-16

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION ,  OSPEDALE SAN RAFFAELE S.R.L. ,  DANA-FARBER CANCER INSTITUTE, INC.

Inventor： ALESSANDRA BIFFI ,  ELEONORA CAVALCA

IPC: G01N33/68 ,  A61K35/76 ,  A61K35/28 ,  A61K9/00

Abstract: The invention features compositions and methods for the treatment and prevention of peroxisomal diseases (e.g., neonatal adrenoleukodystrophy and Zellweger syndrome), including in a subject selected as having increased levels of metallothionein polypeptides. The invention also provides compositions and methods for identifying a subject having a peroxisomal disease involving detecting metallothionein polypeptides or polynucleotdies.

公开(公告)号：US20200182870A1

公开(公告)日：2020-06-11

申请号：US16342354

申请日：2017-10-17

Applicant: OSPEDALE SAN RAFFAELE S.R.L. ,  FONDAZIONE TELETHON

Inventor： Luca BASSO-RICCI ,  Luca BIASCO ,  Alessandro AIUTI

IPC: G01N33/569 ,  G01N33/58 ,  G01N1/28 ,  G01N15/14

Abstract: Use of (i) an anti-CD3 antibody, (ii) an anti-CD56 antibody, (iii) an anti-CD14 antibody, (iv) an anti-CD38 antibody, (v) an anti-CD45 antibody, (vi) an anti-CD90 antibody, (vii) an anti-CD135 antibody, (viii) an anti-CD10 antibody, (ix) an anti-CD11c antibody, (x) an anti-CD19 antibody, (xi) an anti-CD34 antibody, (xii) an anti-CD45RA antibody, (xiii) an anti-CD7 antibody, (xiv) an anti-CD71 antibody, (xv) an anti-CD41/CD61 complex antibody or an anti-CD41 antibody and/or an anti-CD61 antibody (xvi) an anti-CD33 antibody and/or an anti-CD66b antibody, for identifying hematopoietic cell subtypes in an isolated sample, determining the relative frequency of hematopoietic cell subtypes in an isolated sample and/or quantifying the number of cells within hematopoietic cell subtypes in an isolated sample, wherein each of (i) to (xvi) is labelled with a different fluorochrome, wherein when (xvi) is an anti-CD33 antibody and an anti-CD66b antibody, the anti-CD33 antibody and anti-CD66b are labelled with the same fluorochrome, and wherein when (xv) is an anti-CD41 antibody and an anti-CD61 antibody, the anti-CD4 antibody and the anti-CD61 antibody are labelled with the same fluorochrome.

公开(公告)号：US20190211307A1

公开(公告)日：2019-07-11

申请号：US16289095

申请日：2019-02-28

Applicant: Yale University ,  Ospedale San Raffaele S.r.l ,  Fondazione Telethon

Inventor： Richard A. FLAVELL ,  Nicola GAGLIANI ,  Silvia GREGORI ,  Samuel HUBER ,  Chiara Francesca MAGNANI ,  Maria Grazia RONCAROLO

IPC: C12N5/0783 ,  A61K35/17

CPC classification number: C12N5/0637 ,  A61K35/17 ,  C12N2501/2302 ,  C12N2501/231 ,  C12N2501/2315 ,  C12N2501/24 ,  C12N2501/515

Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.

公开(公告)号：US20190175764A1

公开(公告)日：2019-06-13

申请号：US16302120

申请日：2017-05-19

Applicant: Ospedale San Raffaele S.r.l. ,  Fondazione Telethon

Inventor： Anna Christina Kajaste-Rudnitski ,  Francesco Piras

IPC: A61K48/00 ,  A61P43/00 ,  A61P7/06

Abstract: An inhibitor of p53 activation for use in haematopoietic stem and/or progenitor cell gene therapy, preferably wherein the inhibitor is an inhibitor of p53 phosphorylation, more preferably an inhibitor of p53 Serine 15 phosphorylation.

公开(公告)号：US20180273912A1

公开(公告)日：2018-09-27

申请号：US15862773

申请日：2018-01-05

Applicant: Ospedale San Raffaele S.r.l. ,  Istituto Zooprofilattico Sperimentale delle Venezie

Inventor： Lorenzo PIEMONTI ,  Ilaria CAPUA

IPC: C12N7/00 ,  A61K31/351 ,  C07K14/005 ,  A61K31/215 ,  A61K39/12 ,  A61K45/06 ,  A61K39/145

CPC classification number: C12N7/00 ,  A61K31/215 ,  A61K31/351 ,  A61K39/12 ,  A61K39/145 ,  A61K45/06 ,  C07K14/005 ,  C12N2760/16122 ,  C12N2760/16133 ,  C12N2760/16134

Abstract: Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. The inventors provide the first evidence of a causal link between influenza virus infection and the development of type 1 diabetes and/or pancreatitis. This causal link between infection and type 1 diabetes and/or pancreatitis provides various therapeutic, prophylactic and diagnostic opportunities.

公开(公告)号：US20180077922A1

公开(公告)日：2018-03-22

申请号：US15695120

申请日：2017-09-05

Applicant: Glaxosmithkline Intellectual Property Development ,  Ospedale San Raffaele S.r.l. ,  Fondazione Telethon

Inventor： Christina BASFORD ,  Alessandra BIFFI ,  Giuliana FERRARI ,  Natalie Anne FRANCIS ,  Aileen Margaret KIRKPATRICK

IPC: A01N1/02

CPC classification number: A01N1/0221 ,  A01N1/0226 ,  C12N5/0647 ,  C12N2500/62 ,  C12N2510/00

Abstract: The invention relates to compositions for the cryopreservation of transduced haematopoietic cells, in particular transduced haematopoietic stem cells. The invention also relates to methods of preserving the viability of transduced haematopoietic cells using said compositions.

公开(公告)号：US20170165348A1

公开(公告)日：2017-06-15

申请号：US15325124

申请日：2015-07-13

Applicant: Ospedale San Raffaele S.R.L. ,  Fondazione Telethon

Inventor： Alessio Cantore ,  Angelo Leone Lombardo ,  Luigi Naldini

IPC: A61K39/12 ,  C12N15/86 ,  C12N7/04

CPC classification number: A61K39/12 ,  A61K2121/00 ,  C12N7/04 ,  C12N15/86 ,  C12N2740/10052 ,  C12N2740/16041 ,  C12N2740/16052

Abstract: An enveloped viral particle producer or packaging cell, wherein the cell is genetically engineered to decrease expression of MHC-I on the surface of the cell.

公开(公告)号：US20150306142A1

公开(公告)日：2015-10-29

申请号：US14660484

申请日：2015-03-17

Applicant: OSPEDALE SAN RAFFAELE S.R.L.

Inventor： Maria Chiara BONINI ,  Attilio BONDANZA

IPC: A61K35/17 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K48/0091 ,  A61K2039/5156 ,  C12N5/0636 ,  C12N2501/23 ,  C12N2501/2302 ,  C12N2501/2306 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2506/11 ,  C12N2510/00 ,  G01N33/56972 ,  G01N33/6863 ,  Y02A50/412 ,  Y02A50/58

Abstract: It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed.

Abstract translation: 描述用于扩增，检测或分离稀有抗原特异性记忆T细胞群的体外方法。 还描述了获得遗传修饰的记忆T细胞群体的体外方法。 还公开了如此获得的电池的用途。